title: Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients.
abstract: Cytokines play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Among the cytokines that regulate B cell homeostasis is a proliferation-inducing ligand (APRIL). This study aimed to determine whether serum levels of APRIL are raised in patients with SLE and correlate with disease activity or proinflammatory cytokines production, or both. Serum APRIL, interleukin-17 (IL-17), IL-4 and interferon gamma (IFN-γ) levels were measured in forty patients with SLE and 30 healthy controls. Disease activity was assessed by SLE disease activity index (SLEDAI), and results were correlated with serum APRIL levels. Serum APRIL levels were significantly higher in patients with SLE than in healthy controls. Positive correlation was found between serum APRIL levels and total SLEDAI score and anti-dsDNA antibody titers. Moreover, serum APRIL levels was significantly higher in patients with arthritis, mucocutaneous manifestations and proteinuria. APRIL is increased in patients with active SLE accompanying the increase of IL-17 and IFN-γ. Significant positive correlations between serum levels of APRIL and IL-17 and IFN-γ and a negative correlation between serum levels of APRIL and IL-4 were found. The results suggest that APRIL may be an important marker of disease activity in patients with SLE. We provide the analyses of APRIL levels in patients with SLE, suggesting new tools for the diagnosis, prognosis and possible therapeutic management of SLE.
authors.affiliation: Immunology Research Lab, Department of Microbiology and Immunology, Faculty of Medicine, Zagazig University, Zagazig, Egypt, gsboghdadi@zu.edu.eg.
authors.forename: Ghada
authors.initials: G
authors.lastname: Boghdadi
authors.forename: Enass A
authors.initials: EA
authors.lastname: Elewa
mesh_terms: D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000097:blood; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D007371:Interferon-gamma / Q000097:blood; D020381:Interleukin-17 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000175:diagnosis / Q000276:immunology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012720:Severity of Illness Index; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13 / Q000097:blood*; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D000974:Antibodies, Antinuclear; D015415:Biomarkers; C573415:IFNG protein, human; C508598:IL4 protein, human; D018836:Inflammation Mediators; D020381:Interleukin-17; C114631:TNFSF13 protein, human; D053300:Tumor Necrosis Factor Ligand Superfamily Member 13; D015847:Interleukin-4; D007371:Interferon-gamma
references.citation: Nat Immunol. 2002 Sep;3(9):822-9
references.pmid: 12154359
references.citation: Curr Biol. 2000 Jun 29;10(13):785-8
references.pmid: 10898980
references.citation: Clin Immunol. 2010 Apr;135(1):118-24
references.pmid: 20116334
references.citation: Arthritis Rheum. 2003 Dec;48(12):3475-86
references.pmid: 14673998
references.citation: Arthritis Rheum. 2002 Oct 15;47(5):546-55
references.pmid: 12382306
references.citation: Eur J Immunol. 2008 Dec;38(12):3450-8
references.pmid: 19016524
references.citation: Bratisl Lek Listy. 2009;110(3):137-45
references.pmid: 19507632
references.citation: Arthritis Rheum. 1997 Sep;40(9):1725
references.pmid: 9324032
references.citation: Arthritis Res Ther. 2012 Nov 21;14(6):R252
references.pmid: 23171638
references.citation: J Clin Immunol. 2007 Sep;27(5):461-6
references.pmid: 17587156
references.citation: J Exp Med. 1998 Sep 21;188(6):1185-90
references.pmid: 9743536
references.citation: J Exp Med. 2005 May 2;201(9):1375-83
references.pmid: 15851487
references.citation: J Clin Invest. 2005 Nov;115(11):3083-92
references.pmid: 16239971
references.citation: J Clin Immunol. 2005 May;25(3):189-201
references.pmid: 15981083
references.citation: J Rheumatol. 2000 Aug;27(8):1892-5
references.pmid: 10955329
references.citation: Nephrol Dial Transplant. 2011 Oct;26(10):3273-80
references.pmid: 21372259
references.citation: Science. 2001 Sep 14;293(5537):2108-11
references.pmid: 11509692
references.citation: Nature. 2000 Apr 27;404(6781):995-9
references.pmid: 10801128
references.citation: Arthritis Rheum. 2003 Apr;48(4):982-92
references.pmid: 12687540
references.citation: J Exp Med. 1999 Jun 7;189(11):1747-56
references.pmid: 10359578
references.citation: Arthritis Rheum. 1992 Jun;35(6):630-40
references.pmid: 1599520
references.citation: Rheumatology (Oxford). 2003 Aug;42(8):980-5
references.pmid: 12730512
references.citation: J Biomed Biotechnol. 2011;2011:432595
references.pmid: 22028588
references.citation: Arthritis Res Ther. 2010;12(2):111
references.pmid: 20441604
references.citation: Clin Exp Immunol. 2009 Aug;157(2):209-15
references.pmid: 19604260
references.citation: J Clin Invest. 2002 Jun;109(12):1587-98
references.pmid: 12070306
references.citation: Arthritis Rheum. 2009 Jul;60(7):2083-93
references.pmid: 19565488
references.citation: Arthritis Res Ther. 2008;10(4):R97
references.pmid: 18718031
references.citation: Cell Death Differ. 2005 Jun;12(6):637-48
references.pmid: 15846369
references.citation: Ann Rheum Dis. 2009 Jun;68(6):997-1002
references.pmid: 18676986
references.citation: Arthritis Rheum. 1990 May;33(5):634-43
references.pmid: 2346519
references.citation: Ann Rheum Dis. 2005 Jul;64(7):1065-7
references.pmid: 15576416